Page 1 of Clinical Trials for Biological Rituximab, 406 Total Matches

Show/Hide Clinical Trials Which are Not Seeking New Volunteers

1
Withdrawn
Monoclonal Antibody Therapy or Biological Therapy in Treating Patients With Chronic Lymphocytic Leukemia or Multiple Myeloma in Remission After Chemotherapy
Last Updated: May 10, 2011
Condition(s): Leukemia; Multiple Myeloma and Plasma Cell Neoplasm
2
Recruiting
Optimal Management of Rheumatoid Arthritis Patients Requiring Biologic Therapy
Last Updated: May 5, 2010
Condition(s): Rheumatoid Arthritis
3
Completed
A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18
Last Updated: March 10, 2011
Condition(s): B-Cell Lymphomas; Lymphoma, Non-Hodgkin
4
Active, not recruiting
Biological Therapy Plus Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Last Updated: February 6, 2009
Condition(s): Lymphoma
5
Recruiting
GP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma
Last Updated: December 20, 2011
Condition(s): Follicular Lymphoma
6
Recruiting
Long-term Clinical and Biological Evaluation of Patients With Severe Forms of Pemphigus Treated by Rituximab
Last Updated: February 21, 2011
Condition(s): Pemphigus
7
Recruiting
Rotation or Change of Biotherapy After First Anti-TNF Treatment Failure for Rheumatoid Arthritis
Last Updated: June 25, 2010
Condition(s): Rheumatoid Arthritis
8
Not yet recruiting
GM-CSF and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin Lymphoma
Last Updated: July 7, 2009
Condition(s): Lymphoma
9
Recruiting
Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma
Last Updated: March 23, 2012
Condition(s): Anaplastic Large Cell Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Intraocular Lymphoma; Nodal Marginal Zone B-cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Marginal Zone Lymphoma; Small Intestine Lymphoma; Splenic Marginal Zone Lymphoma; Testicular Lymphoma; Waldenstrom Macroglobulinemia
10
Recruiting
An Observational Study of MabThera/Rituxan (Rituximab) and Alternative TNF-Inhibitors in Patients With Rheumatoid Arthritis and an Inadequate Response to a Single Previous TNF-Inhibitor
Last Updated: April 18, 2012
Condition(s): Rheumatoid Arthritis
11
Completed
Low Dose Rituximab as a First Line Biologic Therapy for the Treatment of DMARD Resistant Patients With Rheumatoid Arthritis
Last Updated: May 5, 2012
Condition(s): DMARD Resistant Rheumatoid Arthritis
12
Recruiting
Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, Prednisone, Rituximab, Pegfilgrastim, and Sargramostim as Front-Line Therapy in Treating Patients With Aggressive Non-Hodgkin Lymphoma
Last Updated: February 15, 2011
Condition(s): Lymphoma
13
Recruiting
Rituximab and Autologous Effector Lymphocytes in Non-Hodgkin Follicular Lymphoma in Response to First Line Chemotherapy
Last Updated: November 21, 2011
Condition(s): Follicular Lymphoma; Follicular Non-Hodgkin´s Lymphoma; Autologous Effector Lymphocytes
14
Recruiting
TREatment of degeNerative and Neoplastic Diseases With Rituximab
Last Updated: January 12, 2011
Condition(s): Diffuse Large B Cell Lymphoma
15
Terminated
Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
Last Updated: January 24, 2008
Condition(s): Lymphoma
16
Withdrawn
Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma
Last Updated: October 24, 2006
Condition(s): AIDS-Related Lymphoma; Adult Non-Hodgkin's Lymphoma; Anaplastic Large Cell Lymphoma
17
Recruiting
Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia
Last Updated: April 18, 2012
Condition(s): B-cell Chronic Lymphocytic Leukemia; Refractory Chronic Lymphocytic Leukemia; Stage 0 Chronic Lymphocytic Leukemia; Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia
18
Suspended
GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma
Last Updated: October 22, 2007
Condition(s): Lymphoma
19
Completed
Fludarabine, Cyclophosphamide, and Rituximab or Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia
Last Updated: May 10, 2011
Condition(s): Leukemia
20
Completed
Rituximab and Denileukin Diftitox in Treating Patients With Previously Untreated Stage III or Stage IV Follicular B-Cell Non-Hodgkin's Lymphoma
Last Updated: March 16, 2011
Condition(s): Lymphoma

Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.

The URL of this page is: http://clinicaltrialsfeeds.org/clinical-trials/results/?term=Biological+Rituximab

Page 1 of Clinical Trials for Biological Rituximab, 406 Total Matches

Get the Latest Results via Email or RSS

Subscribe via Web Newsreaders

Browse

Clinical Trials Background

About